382 related articles for article (PubMed ID: 14566678)
1. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
2. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
[TBL] [Abstract][Full Text] [Related]
5. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
6. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
8. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
Akita Y; Kozaki K; Nakagawa A; Saito T; Ito S; Tamada Y; Fujiwara S; Nishikawa N; Uchida K; Yoshikawa K; Noguchi T; Miyaishi O; Shimozato K; Saga S; Matsumoto Y
Br J Dermatol; 2004 Aug; 151(2):472-80. PubMed ID: 15327557
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.
Lim HY; Joo HJ; Choi JH; Yi JW; Yang MS; Cho DY; Kim HS; Nam DK; Lee KB; Kim HC
Clin Cancer Res; 2000 Feb; 6(2):519-25. PubMed ID: 10690533
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
12. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus.
Carlton PS; Gopalakrishnan R; Gupta A; Liston BW; Habib S; Morse MA; Stoner GD
Cancer Res; 2002 Aug; 62(15):4376-82. PubMed ID: 12154043
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer.
Tomozawa S; Tsuno NH; Sunami E; Hatano K; Kitayama J; Osada T; Saito S; Tsuruo T; Shibata Y; Nagawa H
Br J Cancer; 2000 Aug; 83(3):324-8. PubMed ID: 10917546
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
15. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
17. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
Stoner GD; Qin H; Chen T; Carlton PS; Rose ME; Aziz RM; Dixit R
Carcinogenesis; 2005 Sep; 26(9):1590-5. PubMed ID: 15878914
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Mutsaers AJ; Mohammed SI; DeNicola DB; Snyder PW; Glickman NW; Bennett PF; de Gortari AE; Bonney PL; Knapp DW
Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):181-6. PubMed ID: 15664302
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
[TBL] [Abstract][Full Text] [Related]
20. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]